Gensia Sicor Announces Organizational Changes

Gensia Sicor Inc. (Nasdaq: GNSA) today announced two management changes. Frank Becker, a member of Gensia Sicor's Board of Directors, has been appointed to the newly created position of Executive Vice President and Chief Operating Officer and will be responsible for overall chemical, fermentation and pharmaceutical operations. Michael D. Cannon, currently Executive Vice President, USA and President, Gensia Sicor Pharmaceuticals, will move to the newly created position of Executive Vice President and Chief Scientific Officer and will focus on the research and development and regulatory efforts throughout the company. Carlo Salvi, president and chief executive officer stated, "These organizational changes are aimed at providing strategic leadership to key functions of the company, as well as expediting the decision-making process and accelerating the integration of our worldwide operations. With the addition of Frank Becker, we add significant manufacturing and operational depth to our current management team and are now well positioned to fully realize Gensia Sicor's potential and to aggressively pursue the opportunities of the marketplace." Mr. Becker is the founder of Greenfield Chemical, Inc., which provides procurement and sourcing services to the pharmaceutical industry, as well as consulting services to chemical manufacturers to help improve manufacturing efficiencies, production planning, capital plans and strategic planning of assets. Mr. Becker retired from Abbott Laboratories in 1997, where he was Vice President, Chemical Process Research and Development. Mr. Becker holds a Bachelor of Science degree in Chemical Engineering from Purdue University and a MBA from the University of Chicago. Mr. Becker was awarded a Distinguished Engineering Award in 1997 from Purdue and is the holder of thirteen patents. Gensia Sicor Inc. is a vertically integrated pharmaceutical company with proven expertise in the development, manufacturing and marketing of injectable pharmaceuticals and in the production of active pharmaceutical ingredients utilizing synthesis or fermentation. The company is focused on the worldwide oncology and injectable pharmaceutical markets. Gensia Sicor's commercial pharmaceutical businesses include Gensia Sicor Pharmaceuticals, Inc., a California-based manufacturer and marketer of multisource injectable drugs, SICOR-Societa Italiana Corticosteroidi S.p.A. and Diaspa S.p.A., both of Milan Italy, and Sicor de Mexico, S.A. de C.V. in Toluca, Mexico all which produce active pharmaceutical ingredients, and Lemery, S.A. de C.V. in Mexico City which manufactures injectable and oral finished multisource drug products. Gensia Sicor's company offices are located in Irvine, CA. This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements and those matters set forth in the risk factors section of Gensia Sicor's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements. For more information on the Company, visit Gensia Sicor's new web site at News releases are also available at no charge through PR Newswire's News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by Gensia Sicor, call 800-758-5804, extension 354050. Please retain these numbers for future reference. ots Original Text Service: Gensia Sicor Inc. Internet: Contact: Laurie W. Little of Gensia Sicor Inc., Tel.: (in the USA) 949-455-4879; or Carolyn Bass or Jim Byers, Tel.: (in the USA) 415-296-7383, or Patricia Walsh or Mark Owen, Tel.: (in the USA) 212-850-5600, all of Morgen-Walke Associates, Inc. Company News On-Call: or fax, 800-758-5804, ext. 354050 Web site:


Prague, Central Bohemia region and Czech Republic


Subscribe for free

Important notice:
Subscribers please note that material bearing the label "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" label. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents.